A venture capital firm based in the Mountain West has approximately $300 million in total assets available for investment. The firm typically makes equity investments in 3 to 4 companies every year, and it has flexibility in terms of capital structures. The average first investment in a company is $2 million- $3 million, though it can invest more or less, depending on the opportunity. The firm prefers to invest in seed and series A (early-stage) companies as an initial investment in a company, though it sometimes makes a first investment in a series B or C round. The firm primarily invests in US-based companies, but it will also consider global companies with a US presence.

The firm is currently looking for investment opportunities in medical devices, biopharma and diagnostics. The firm generally makes investments in product-focused companies in pre-clinical stages with prototypes or other available proof-of-concept work completed. It generally likes to invest in companies that can reach the market with the capital raised from this round of financing. The firm prefers device companies with a 510(k) pathway for regulatory approval, and it will opportunistically consider companies with PMA devices.

The firm seeks to invest in small, early-stage companies with a lean but strong and qualified management / execution team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Chicago-based VC firm is investing from a $250m fund, and is interested in a variety of sectors including the life science field. For life science investments, the firm typically allocates $2-15 million, and prefers to invest in Series B-C rounds. The firm invests in the USA and Canada.

The firm is presently focused on technologies that involve an IT/software component, across the medical devices, diagnostics, and healthcare services sectors in addition to pure digital health opportunities. The firm is open to opportunities in any clinical indication. The firm is only interested in devices and diagnostics that have in-human data.

In the life science sector, the firm is not interested in early-stage opportunities; however the firm is open to both companies with an approved product on the market, and companies with a product in late-stage clinical trials. The firm takes the strength of the management team into consideration.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm that founded in 2000 and is based in the US Midwest has assets under management of over $250 million, and closed a new fund in 2015. The fund typically makes equity investments in U.S.-based companies, with portfolio companies located on both coasts and throughout the central part of the country. The firm will consider investing at all stages, with a focus on seed and early-stage investments, including founding companies. Investment size is up to $12 million throughout a portfolio company’s path to liquidity.

The fund is currently looking for new investment opportunities in the life science space, with a specific focus on biopharmaceuticals and therapeutic medical devices. The firm has previously invested in drugs to treat cancer and cardiac disorders, and in minimally invasive medical devices. The fund does not invest in diagnostics, though may be interested in technology with real-time feedback for procedures.

The fund focuses on identifying and shaping early-stage life science companies in the series A/B rounds to create significant shareholder value. Because of its extensive operating expertise, the fund is able to help entrepreneurs achieve near-term objectives that position their companies for exit.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Europe-based private equity firm founded in 2009 has a fund focused solely on oncology. The firm aims to fill the gap between equity and acquisition, and would be the first to get involved in assets that are seeking to spin-out of universities or research institutes. The firm typically acquires stakes and identifies ways to aggregate oncology technologies. The firm’s investment size ranges from $10M-$25M dependent on the company and product. The firm typically seeks co-investors to participate in a round. The firm has predominantly invested in companies based in the UK, though is open to investments on a global level, and is particularly seeking new opportunities in the US.

The firm invests in all sectors and subsectors of technology in oncology – therapeutics, 510K and PMA medical devices, diagnostics, and healthcare IT, along with oncology technology in palliative care. The firm is particularly loyal to its portfolio companies, as it typically makes investments in early-stage post proof-of-concept companies, and remains in the investment until commercialization.

The firm will help fill the management team, and may actively manage; takeover the management; participate in the advisory board; and/or advise the company after an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.